Dyslipidemia is defined as elevation of the total cholesterol, the “bad” low-density lipoprotein (LDL) cholesterol and the triglyceride concentrations, and a decrease in the “good” high-density lipoprotein (HDL) cholesterol concentration in the blood. Numerous factors and causes can lead to an abnormality in the levels of lipids in the blood such as genetic predisposition, diet, age and gender, type II diabetes. Common symptoms that may be encountered in relation to dyslipidemia include corneal opacification, corneal arcus, xanthomas, balance impairment, pain in the calf when walking, dizziness and confusion.
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Dyslipidemia (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Dyslipidemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Purchase this report at: https://www.themarketreports.com/report/buy-now/1514667
List of Figures
- Number of Products under Development for Dyslipidemia, H1 2019
- Number of Products under Development by Companies, H1 2019
- Number of Products under Development by Universities/Institutes, H1 2019
- Number of Products by Top 10 Targets, H1 2019
- Number of Products by Stage and Top 10 Targets, H1 2019
- Number of Products by Top 10 Mechanism of Actions, H1 2019
- Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019
- Number of Products by Routes of Administration, H1 2019
- Number of Products by Stage and Routes of Administration, H1 2019
- Number of Products by Molecule Types, H1 2019
- Number of Products by Stage and Molecule Types, H1 2019
Got a question; ask us at: https://www.themarketreports.com/report/ask-your-query/1514667